42.48
전일 마감가:
$42.93
열려 있는:
$42.65
하루 거래량:
407.65K
Relative Volume:
0.52
시가총액:
$1.58B
수익:
$272.30M
순이익/손실:
$-5.14M
주가수익비율:
-259.82
EPS:
-0.1635
순현금흐름:
$42.76M
1주 성능:
-0.61%
1개월 성능:
+18.33%
6개월 성능:
-9.19%
1년 성능:
+35.42%
Harrow Inc Stock (HROW) Company Profile
명칭
Harrow Inc
전화
615.733.4731
주소
1A BURTON HILLS BLVD, NASHVILLE, CA
Compare HROW vs TAK, HLN, TEVA, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
|
HROW
Harrow Inc
|
42.48 | 1.58B | 272.30M | -5.14M | 42.76M | -0.1635 |
|
TAK
Takeda Pharmaceutical Co Adr
|
16.56 | 52.88B | 29.91B | 1.30B | 3.49B | 0.4056 |
|
HLN
Haleon Plc Adr
|
9.76 | 42.98B | 14.54B | 2.22B | 2.58B | 0.4871 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.95 | 38.37B | 17.53B | 1.58B | 444.18M | 1.3457 |
|
ZTS
Zoetis Inc
|
75.56 | 31.68B | 9.51B | 2.64B | 2.14B | 6.0361 |
|
UTHR
United Therapeutics Corp
|
547.06 | 23.22B | 3.17B | 1.29B | 1.01B | 27.09 |
Harrow Inc Stock (HROW) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-11 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-06-12 | 개시 | BTIG Research | Buy |
| 2025-06-10 | 개시 | William Blair | Outperform |
| 2025-02-06 | 개시 | H.C. Wainwright | Buy |
| 2024-12-04 | 재확인 | B. Riley Securities | Buy |
| 2024-04-11 | 개시 | Craig Hallum | Buy |
| 2022-09-08 | 재개 | B. Riley Securities | Buy |
| 2021-10-14 | 재개 | B. Riley Securities | Buy |
| 2021-09-24 | 개시 | Aegis Capital | Buy |
| 2021-07-02 | 개시 | Ladenburg Thalmann | Buy |
모두보기
Harrow Inc 주식(HROW)의 최신 뉴스
Analysts Are Optimistic We'll See A Profit From Harrow, Inc. (NASDAQ:HROW) - 富途牛牛
HROW Q1 2026 Earnings: EPS Misses Estimates Sharply Amid Operational ChallengesQuarterly Earnings - dars.gov.et
HROW News | HARROW INC (NASDAQ:HROW) - ChartMill
Harrow relaunches biosimilar Byooviz in the US - Eyes On Eyecare
Harrow Announces Commercial Launch of BYOOVIZ® in the United States - Sahm
Enterprise value to EBITDA forward of Harrow, Inc. – NASDAQ:HROW - TradingView
Price to book forward of Harrow, Inc. – NASDAQ:HROW - TradingView
Price to earnings forward of Harrow, Inc. – NASDAQ:HROW - TradingView
Price to sales forward of Harrow, Inc. – NASDAQ:HROW - TradingView
Enterprise value to revenue forward of Harrow, Inc. – NASDAQ:HROW - TradingView
Lake Street Maintains Harrow(HROW.US) With Buy Rating, Maintains Target Price $60 - Moomoo
Harrow Expands Retina Portfolio With US Launch of Byooviz - marketscreener.com
Harrow (HROW) Launches Byooviz, FDA-Approved Biosimilar - GuruFocus
Harrow (HROW) Launches BYOOVIZ Biosimilar in U.S. Market - GuruFocus
A first FDA-approved eye biosimilar returns to U.S. sales - Stock Titan
A Look at Harrow Inc (HROW) After 3.2% Gain -- GF Value $42.31 v - GuruFocus
Cantor Fitzgerald Maintains Harrow(HROW.US) With Buy Rating, Maintains Target Price $88 - Moomoo
Harrow, Inc. Actuals & Estimates (NASDAQ:HROW) - TradingView
HROW Forecast — Price Target — Prediction for 2027 - TradingView
How Grow Funds’ Exit and Weaker Earnings Recast Harrow’s (HROW) Growth Narrative and Governance Choices - simplywall.st
Harrow Inc (HROW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
GROW Small Cap Equity Fund Covered Its Position in Harrow (HROW) in Q1 - Insider Monkey
Form 4 Harrow Health Inc For: 22 June By Investing.com - Investing.com Australia
[Form 4] HARROW, INC. Insider Trading Activity - Stock Titan
Harrow (HROW) director Adrienne Graves receives 5,248 RSUs as compensation grant - Stock Titan
Harrow (HROW) director granted 5,248 restricted stock units as compensation - Stock Titan
Form 8K Harrow Health Inc For: 22 June By Investing.com - Investing.com Australia
Harrow elects directors and approves executive compensation at annual meeting - Investing.com
Harrow, Inc. (NASDAQ: HROW) 2026 Annual Meeting Results: Shareholder Votes and Key Decisions from Form 8-K Filing – Minichart - Minichart
Harrow (HROW) investors back all 2026 director, pay and auditor proposals - Stock Titan
Harrow Inc (HROW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
$Harrow (HROW.US)$ i shouldve put more in - Moomoo
Spotlight On Harrow And 2 Other Growth Stocks With Strong Insider Backing - simplywall.st
Harrow Inc (HROW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Harrow Inc (HROW) Valuation: PE, PB & Fair Value Analysis - TradingKey
Harrow Inc (HROW) Institutional Confidence - TradingKey
Harrow Inc (HROW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Harrow Inc (HROW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Harrow Inc (HROW) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Harrow Inc (HROW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Is Harrow, Inc. (HROW) A Good Stock To Buy Now? - Insider Monkey
Can Harrow’s (HROW) VERKAZIA Relaunch Redefine Its Niche Ophthalmic Strategy? - Yahoo Finance
Harrow Adds Another Piece To Ophthalmology Strategy - Benzinga
HROW Stock Rises on Relaunch of Ophthalmology Drug Verkazia in the US - TradingView
HROW Stock Rips Higher As Traders Digest Mixed Quarter - timothysykes.com
Analysts Are Bullish on Top Healthcare Stocks: Harrow Health (HROW), GeneDx Holdings (WGS) - The Globe and Mail
Harrow Re-Launches VERKAZIA® (cyclosporine ophthalmic - GlobeNewswire
Harrow Inc (HROW) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):